Raltegravir 400mg Tablets

Raltegravir 400mg Tablets is a pioneering antiviral medication belonging to the class of HIV-1 integrase strand transfer inhibitors (INSTIs). It was the first drug of its kind to be approved, offering a novel mechanism of action for suppressing the Human Immunodeficiency Virus (HIV). This therapeutic agent works by specifically targeting and inhibiting the viral integrase enzyme. This enzyme is essential for the replication of the virus because it facilitates the insertion (integration) of HIV genetic material into the DNA of human immune cells (CD4 T-cells). By blocking this critical step, the medication prevents the pathogen from establishing a permanent infection in the cell and halts the production of new viral particles. This targeted interruption leads to a rapid and profound reduction in viral load. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for constructing robust antiretroviral regimens, offering a life-saving option for both treatment-naïve patients and those whose virus has developed resistance to other drug classes.

The 400mg film-coated tablet is the standard formulation used in the traditional twice-daily dosing schedule. Unlike many other antiretrovirals that are metabolized by the cytochrome P450 system, the active ingredient is primarily metabolized via glucuronidation (UGT1A1). This unique metabolic pathway results in significantly fewer drug-drug interactions, making this antiviral an excellent choice for patients with complex medical profiles or those taking multiple other medications.

Indications / Uses of Raltegravir 400mg Tablets

This product is commonly prescribed for the specialized management of HIV-1 infection:

• Treatment of HIV-1 Infection: It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 2 kg. It is effective in both treatment-naïve patients (those new to therapy) and treatment-experienced patients (those whose prior treatments have failed).
• Post-Exposure Prophylaxis (PEP): Due to its rapid onset of action and favorable side effect profile, the drug is frequently included in 28-day regimens to prevent HIV infection after potential occupational or non-occupational exposure (e.g., needlestick injuries).

Key Features

• First-in-Class Integrase Inhibition: The primary feature of the medication is its ability to block the strand transfer step of viral DNA integration, a mechanism distinct from protease or reverse transcriptase inhibitors.
• Rapid Viral Suppression: Clinical data demonstrates that regimens containing this inhibitor often achieve undetectable viral loads faster than many comparator regimens.
• Minimal Drug Interactions: Because it is not a CYP450 substrate, inhibitor, or inducer, it can be safely co-administered with a wide variety of other drugs (e.g., methadone, hormonal contraceptives).
• Twice-Daily Dosing: The 400mg unit is designed to be taken twice a day (every 12 hours) to maintain consistent therapeutic levels in the blood.
• High Tolerability: It generally has a favorable lipid profile (minimal effect on cholesterol) and is well-tolerated by most patients.

Storage for Raltegravir 400mg Tablets

To preserve the pharmacological stability and ultimate potency of the active ingredients, the tablets should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Deviations are permitted between 15°C and 30°C (59°F to 86°F). It is vital to keep the bottle tightly closed to protect the medication from moisture, and the desiccant should remain in the bottle if provided. For maximum safety, always store the product in a secure, high location that is strictly out of the reach and sight of children and pets.

Important Note on Raltegravir 400mg Tablets

The administration of Raltegravir 400mg Tablets requires awareness of potential skin and immune reactions. Severe, potentially life-threatening skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported. Patients developing a rash associated with fever, malaise, fatigue, or mucosal blistering must discontinue the therapy immediately and seek urgent medical care.

Immune Reconstitution Inflammatory Syndrome (IRIS) may occur when starting treatment; as the immune system recovers, it may vigorously attack lingering infections (like TB or pneumonia), causing profound inflammation.

The drug has been associated with elevated creatine kinase (CK) levels and rare cases of myopathy and rhabdomyolysis (muscle breakdown). Patients should report unexplained muscle pain or weakness. Crucially, do not take the tablets with aluminum or magnesium-containing antacids, as they bind to the active compound in the gut and significantly reduce its absorption. Calcium carbonate antacids generally do not have this effect. This treatment is not a cure for HIV; it suppresses the virus but does not eradicate it, so transmission is still possible if viral load is not fully controlled. By strictly following these professional guidelines and the twice-daily schedule, patients can maximize the viral suppression provided by this advanced formulation.